Cero Therapeutics Holdings Q3 2026 Results: Turns Profitable, Net Income $4.02M
CERo Therapeutics Holdings, Inc. is an emerging growth company focused on developing its lead product candidate, CER-1236. As of November 13, 2026, the company reported 83,309,742 shares of common stock outstanding and noted the impact of its delisting from Nasdaq as a significant risk factor.
- Key figure
- Net income $4.02M